sST2 Predicts Outcome in Chronic Heart Failure Beyond N-proBNP and High-Sensitivity Troponin T

Michele Emdin*, Alberto Aimo, Giuseppe Vergaro, Antoni Bayes-Genis, Josep Lupon, Roberto Latini, Jennifer Meessen, Inder S. Anand, Jay N. Cohn, Jorgen Gravning, Lars Gullestad, Kaspar Broch, Thor Ueland, Stale H. Nymo, Hans-Peter Brunner-La Rocca, Rudolf A. de Boer, Hanna K. Gaggin, Andrea Ripoli, Claudio Passino, James L. Januzzi

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND Soluble suppression of tumorigenesis-2 (sST2) is a biomarker related to inflammation and fibrosis. OBJECTIVES This study assessed the independent prognostic value of sST2 in chronic heart failure (HF). METHODS Individual patient data from studies that assessed sST2 for risk prediction in chronic HF, together with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT), were retrieved. RESULTS A total of 4,268 patients were evaluated (median age 68 years, 75% males, 65% with ischemic HF, 87% with left ventricular ejection fraction [LVEF] <40%). NT-proBNP, hs-TnT, and sST2 were 1,360 ng/l (interquartile interval: 513 to 3,222 ng/l), 18 ng/l (interquartile interval: 9 to 33 ng/l), and 27 ng/l (interquartile interval: 20 to 39 ng/l), respectively. During a 2.4-year median follow-up, 1,319 patients (31%) experienced all-cause death (n = 932 [22%] for cardiovascular causes). Among the 4,118 patients (96%) with available data, 1,029 (24%) were hospitalized at least once for worsening HF over 2.2 years. The best sST2 cutoff for the prediction of all-cause and cardiovascular death and HF hospitalization was 28 ng/ml, with good performance at Kaplan-Meier analysis (log-rank: 117.6, 61.0, and 88.6, respectively; all p < 0.001). In a model that included age, sex, body mass index, ischemic etiology, LVEF, New York Heart Association functional class, glomerular filtration rate, HF medical therapy, NT-proBNP, and hs-TnT, the risk of all-cause death, cardiovascular death, and HF hospitalization increased by 26%, 25%, and 30%, respectively, per each doubling of sST2. sST2 retained its independent prognostic value across most population subgroups. CONCLUSIONS sST2 yielded strong, independent predictive value for all-cause and cardiovascular mortality, and HF hospitalization in chronic HF, and deserves consideration to be part of a multimarker panel together with NT-proBNP and hs-TnT. (c) 2018 by the American College of Cardiology Foundation.
Original languageEnglish
Pages (from-to)2309-2320
Number of pages12
JournalJournal of the American College of Cardiology
Volume72
Issue number19
DOIs
Publication statusPublished - 6 Nov 2018

Keywords

  • heart failure
  • NT-proBNP
  • prognosis
  • sST2
  • troponin T
  • REDUCED EJECTION FRACTION
  • SOLUBLE ST2
  • PROGNOSTIC VALUE
  • NATRIURETIC PEPTIDES
  • AMBULATORY PATIENTS
  • TASK-FORCE
  • THERAPY
  • BIOMARKERS
  • ASSOCIATION
  • EPIDEMIOLOGY

Fingerprint

Dive into the research topics of 'sST2 Predicts Outcome in Chronic Heart Failure Beyond N-proBNP and High-Sensitivity Troponin T'. Together they form a unique fingerprint.

Cite this